Biocon sees FY20 as a strong year in terms of generics biz growth in US

Name: Biocon sees FY20 as a strong year in terms of generics biz growth in US
Uploaded: 2019-04-26T08:00:20+00:00
Duration: 6 min 43 s
Channel: CNBC-TV18
Description: “Expect FY20 to be a strong year in terms of growth of our generics business in US, supported strongly with our API business” said Kiran Mazumdar Shaw, CMD, Biocon.

CNBC-TV18

“Expect FY20 to be a strong year in terms of growth of our generics business in US, supported strongly with our API business” said Kiran Mazumdar Shaw, CMD, Biocon.

Category

Recommended